Sydney, Sep 26, 2007 (RWE via COMTEX) -- NURPF | charts | news | PowerRating -- (RWE Australian Business News) Neuren Pharmaceuticals (ASX:NEU) today announced that the first Australian patient had entered the Phase 3 clinical trial of its lead compound Glypromate, in development to reduce cognitive impairment after cardiac surgery.
